µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ !\6<kQg#
1z5Oi u
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ (/a#1Pd&
:+qd>;yf#
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ &{uj3s&C
45aUz@
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© l3O!{&~K
Z.l4<
1. CD4 Id}/(Pkq
rn9n _)
2. T cell receptor(TCR) 9>6DA^
R9z:K_d,
3. immunoglobulin superfamily (IgSF) ?XIB\7
}
)4MM>Q
4. selectin SYE+A`a
NxW
Dw
5. anti-idiotypic antibody (¦ÁId) 2if7|o$=
/Bw
<?:
6. major histocompatibility complex(MHC) e=^^TX`I
K'_qi8
Z
7. immunotolerance \}Al85
9]Fi2M
8. biological reponse modifier(BRM) U
#C@&2
Iz^vt#b
9. immune reponse gene (Ir gene) 'L@kZ
vvI23!H
10. reshaped antibody (or reconstituted antibody) :o 8XG
)GYnQoV4
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© nZ'-3
=%ok:+D]
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ @PT([1C
V1&qgAy~
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? GoLK
95"]
QR2S67-
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Z%Fc
-KVt
rJ)j./c
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? @-ml=S7;Sz
DL*vF>v
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) AP1&TQ,&
5-hnk'
~
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 3K=%I+G(4
K9{RU4<
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? <D[0mi0
{Q}F.0Q
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? _U_O0@xi
o! l Ykud
¡¡ o1vK2V
q;}iW:r&Q
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ w_f.\\1r
%vv`Vx2
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? 8t3m$<7
AhD C5ue=
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? sH.=Faos
@c-
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ V2!0),]B
xeL"FzF:V
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ f4
qVUU
?G5,}%
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ lXg5UrW
{l)$9!
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© j.ucv
D#G%WT/"
1. CD8 c:.~%AJx
FJDE4
8Vi
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) "(3u)o9
{9y
f0n
3. immunoglobulin fold(Ig fold) m`9nDiV
f-G)pHm
4. cadherin (Ca-dependent cell adhesion moleculers) K8aqC{
b,^Gj]7
5. idiotype-anti-idiotypic antibody immune network theory -?-XO<I
g"Y_!)X
6. HLA class II antigen {G Jl<G1
G0{Z@CvO'
7. complementarity-determining region (CDR) :oXSh;\
J\r\_P@;c
8. perforin(or pore-forming protein ,PFP) QJ3#~GYNr
\4L ur
9. high affinity IL-2 receptor ~x^y5[5{
*^uK=CH1?(
10. artificial active immunization 4kjfYf@A
R(d<PlZ
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© N#K)Z5J)b
d
MH_:jb
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠr*+~(83k
3uocAmY
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 z_!IA
] v
o{G*7V@H
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ M
bWby'
=mO5~~"W+v
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ ^e8xg=8(
(dq_,LI
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) . vb##D
cu N9RG
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ YGJ!!(~r
z2iMpZ
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? In1W/?
1'qXT{f/~
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ :C*}Yg
~_fc=^o
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ pi?/]}:
M0w Uis:`
¡¡ qWhW4$7x
YVMvT>/,
g8Ex$,\,
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 9^XZ|`
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ I?'*vAW<
p(n0(}eVC'
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ G'\[dwD,u
\6|y~5Hw{r
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© gy}3ZA*F
8J3#(aBm
1. immunoglobulin gene rearrangement !, BJO3&
$`|hF[tv
2. the common chain of cytokine receptor (or a cytokine receptor ?{ )'O+s
&V?+Y2
subunit shared by some cytokine receptors) KR( apO
{N2GRF~c-y
3. flow cytometry(FCM) }dN\bb{#
xw8k<`
4. carrier effect !0l|[c4 e>
xRWfZ3E
#
5. positive selection of T lymphocytes in thymus PB^rniYh
X"TL'"?fo
6. mouse TH1(Th1) and TH2(Th2) subsets =78y*`L
k M/:n
7. perforin (pore-forming protein ,PFP) w
~+*Vd~U
X?haHM#]
8. ADCC(antibody-dependent cell-mediated cytotoxicity) %`b
s<ZWT
dzIBdt
h
9. SH-2(src-homology region 2)
ck;:84
NN7KwVg
10. Ab2¦Â (internal image) D\G 8p;
a0ms9%Y;Q[
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© UT@Qo}:
F[coa5
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? $~8gh>`]
dU-:#QV6
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? qg j;E=7
3SY1>}(Y
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ!IJ
YaQ6z
n'ZPB
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ *fY*Wy9
# 9bw
'm
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠjXx~
5
sB0]lj-[Un
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) Ks3YrKk;p
=n.&N
ÃâÒßѧרҵ£º bv7)[,i
Vb\^xdL>
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ fm#7}Y
y@}WxSK*0
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? l/?bXNt
tv-SX
=T
´«È¾²¡Ñ§×¨Òµ£º :"Vmy.xq
B|syb!g
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ #Hy9 ;Q
.mnkV -m
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ M3eSj`c3
J^WX^".E
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ k-4z2qB
{DVMs|5;^
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? ']!wc8m1"
;Gp9
? 0
uKY1AC__
$U&p&pgH=W
WM9({BZ
4<EC50@.
z3^gufOkQ
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ RP^L.X(7^
cr18`xU
ÃâÒßѧÊÔÌâ B<|Vm.D
cNKGEm
;z
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© PTQN.[bBh
1n)YCSA
1. Fas(CD95)/FasL tHvP0RxM
(j%"iQD
2. common chain of cytokine receptor sVlQ5M oo(
do l8O
3 . TCR/CD3 complex Y 6jgAq
wgQx.8 h>
4. negaive selection of thymocytes iII%!f?{[
F$s:
\N
5. artificial active immune 1O2V!?P
M^n^wz
6. anti-idiotypic 4?_^7(%p
Fbw.Y6
7. IgSF 6,l5Q
Nc^:v/(P
8. Integrin 7Zft]C?|@
7<*g'6JG[
9. chemokine Jg&f.
$GD
Q1&Z
10. B7/CD28 F:Yp1Wrb <
jU{~3Gn?
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© 0Fs2* F
S
_Q*,~ z~
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ FW4#/H
-^>7\]
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ U_wIx
:?gp}.
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 4=njM`8Y'
#,SPV&
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ Ibv`/8xh
)|&FBz;
dFk$rr>q
h\|T(597.
?0d#O_la
3
/9ZU_y4&3f
cZ,}1?!
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ e'3y^Vg
&3 x
[0DV
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© xE6hE'rh.O
N1JM[<
PP
1. B7/CD28 /b."d\
V+$fh2t
2. Th1 subset nCLEAe$W\=
b%xG^jUXsX
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© &Y2Dft_K
pE{Ecrc3|
4. antibody affinity maturation -T>i5'2)
8)YDUE%VH
5. AP-1
tPFj[Y~Iy
d*LW32B@
6. single chain variable fragment£¨ScFv£© .i3_D??
(JT
273
7. NK cell receptor 7DWGYvv[
kK.[v'[>&
8. Zinkernagel-Doherty phenomenon
^]?juL
{vp*m:K
9. Ig fold 5I/lF oy7
"Ve9\$_s
10. CD40/CD40L vywpX^KPv
pL2{zW`FDh
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© qTe@?j
8Y/1+-
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 8;x0U`}Ez(
9u%(9Ae
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ aAgQ^LY
'%y;{,g*
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ $t0JfDd6Ky
upGLZ#
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ LHSbc!Y'.
jW>K#vj
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ }ldpudU
6i@* L\
Dl
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ~nApRC)0
`i<Z<
<c>
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ \} _,g
aP#/%
MfO:BX@$
%^[D+1ULb
B:Hr{%O
ri6KD
13+.>
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ fElFyOo+
UqNUX?(
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© F6aC'<#/
1xInU_SPf
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 73Hm:"Eqd
;%;||?'v
1.Co-stimulators (or co-stimulating molecules) -+0kay%
RGrQ>'RL
2.NK-kB Je}0KW3G9L
c94=>p6
3.Immunoglobulin superfamily Ov^##E
_W^;a
4.antigen-presenting cell (APC) _*MK"
]
Y!x7
5.death domain n2EPx(~
*if
z@8C }
6.CCR and CXCR ambr}+}
%"eR0Lj+zq
7.Lectin (or mitogen) L#zD4L
2TNK
8.Clusters of differentiation, CD) !?=U{^|7y
;lvcg)}l
9.B7 family uxB`
5OzEY7K)
10.Cytotoxic T lymphocyte, CTL) om2N*W.gk
{_/ o' 6
11.IL-15 and IL-15 receptor (IL-15R) =^i K^)
D:f=Z?L)>
12.MHC restriction o+7)cI
y^ |u'XK
13.Affinity-chromatography 7eAV2.
JO+tY[q
14.Cyctosprin A, CsA @OkoT:
+{RTz)e?*
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) &J
catI
f:ObI
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {(!JYz~P
w.a9}GC
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 WFh.oe8
oJ\g0|\qwe
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
| @$I<
Dzf\m>H[
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ b%%r`j,'JE
#$x
,PeG
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© o3/o2[s
jr? /wtw
ÃâÒßѧרҵ£º %,_ZVgh0
lz~^*\ F
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ C| ~A]wc=
N=KtW?C
Ïû»¯ÄÚ¿Æ£º 1o%#kf
K F_fz
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /*T^7Y&
YWl#!"-
ѪҺ²¡Ñ§×¨Òµ£º U?le|tK
p eO@ZKmM
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ b>OB}Is
W~;Jsd=f
AX8~w(sv
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ J
W@6m
e^>>"tr
(רҵ»ù´¡: ÃâÒßѧ) "Zgwe,#
7,+eG">0
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) BX0lk
:^3 )[.m
1. ADCC(antibody dependent cell-mediated cytotoxicity) 0N$7(.
5MB`yRVv
2. »·æß¾úËØ(cyclosporin) @/.#
/
7s
xX?u
3. KIR(killer cell inhibitory receptor) hi1Ial\Y
?l/6DT>e
4. HLDA(human leucocyte differentiation antigen) Bdw33z*m
iH }-
5. Interleukin 18(IL-18) a.Z@Z!*
I/Vw2
6. ÕûºÏËØ(integrin) \
N*([{X
R VatGa0
7. Fas/FasL +twoUn{#
6WY/[TC-
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) XGx[Ny_A2
\FVfV`x
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) p0@^1
^z{szy?Fg
10. Th1/Th2 13X}pnW
^<CVQ8R7
11. »ùÒòÒßÃç(DNAÒßÃç) Gaix6@X6'
k XSX<b <%
12. chemokines and chemokine receptor l*1|B3#m!
|"gL{De
13. ÃâÒßÄÍÊÜ p'K`K\X
l{k_;i!D
14. ¹²´Ì¼¤·Ö×Ó XIdh9)]^}
[s(D==8
15. ËÀÍö½á¹¹Óò(death domain) =fcg4h5(
p~$cwbQ!
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) $H)^o!
dJ"M#X!Zu
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? HuevDy4
RxP H[7oZ
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠk;l3^kTy
vY4sU@+V
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 3
z8i0
'$9o(m#
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ _?tpO61g>
/{^k8
Q
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå /WuYg
OI
1R2IlUlzFr
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ \2\{c1df
jf9+H!?^N
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£